<DOC>
	<DOCNO>NCT00729495</DOCNO>
	<brief_summary>Phase I study design test hypothesis overencapsulated celecoxib 200 mg qd bioequivalent commercial celecoxib 200 mg qd . Approximately 90 healthy volunteer randomize yield approximately 80 completers . The study open label , randomize , 2-way crossover single dosing follow 7-day washout period treatment arm</brief_summary>
	<brief_title>Phase I Study Evaluate Bioavailability Overencapsulated Celecoxib</brief_title>
	<detailed_description />
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Healthy male female subject 1855 yr . age ( inclusive ) Screening Visit Body Mass Index ( BMI ) great equal 19 less equal 30 kg/m2 weight great equal 50 less equal 100 kg Clinically normal physical exam laboratory measurement Subject receive another investigational drug within 4 week preceeding study plan participate another study time period study Any significant medical psychiatric condition could affect interpretation PK data , otherwise would contraindicate participation clinical trial Any GI disease , abnormality gastric surgery may interfere gastric emptying , motility drug absorption Subject donate unit blood plasma within 3 month prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Phase I ,</keyword>
	<keyword>Healthy</keyword>
	<keyword>Volunteer</keyword>
	<keyword>Study</keyword>
</DOC>